Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT07477704
Active, not recruiting Phase 2

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07477704 · tracked via the Priya Life Science USA tracker
Sponsor
Regeneron Pharmaceuticals
Phase
Phase 2
Started
2026-06-17
Last updated
2026-10-15

Condition(s) studied

Hypercholesterolemia

Investigational drug(s) / intervention(s)

Alirocumab →

Alirocumab: Administered per the protocol

Study summary

This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

The aim of the study is to see how safe and effective alirocumab is when given weekly to adult participants who have hypercholesterolemia.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drug once a week
* How much study drug is in the blood at different times

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Key Inclusion Criteria: 1\. Participant has elevated LDL-C level, as defined in the protocol Key Exclusion Criteria: 1. Participant plans to initiate or change dose of lipid-lowering therapy 2. Use of any PCSK9 inhibitors NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply

Primary outcome measure(s)

  • Percent change in LDL-C — From Baseline through Week 12

Trial sites (34)

FacilityCityRegionStatus
Pinnacle Research Group Anniston Alabama
Cullman Clinical Trials Cullman Alabama
Anaheim Clinical Trials Anaheim California
Cenexel CNS Los Alamitos California
Diablo Clinical Research - Flourish Research Walnut Creek California
Tampa Bay Medical Research Clearwater Florida
Southwest General Healthcare Center Fort Myers Florida
Precision Clinical Research Sunrise Florida
K2 Medical Research The Villages The Villages Florida
Center for Advanced Research and Education Gainesville Georgia
Balanced Life Health Care Solutions Lawrenceville Georgia
East-West Medical Research Institute Honolulu Hawaii
L-MARC Research Center Louisville Kentucky
Tandem Clinical Research Marrero Louisiana
Mercury Street Medical Group, PLLC Butte Montana
Velocity Clinical Research - Omaha Omaha Nebraska
Palm Research Center, Mountainview Medical Center Las Vegas Nevada
Velocity Clinical Research - Durham Durham North Carolina
Accellacare of Wilmington Wilmington North Carolina
Ohio Clinical Trials Columbus Ohio
AMR Norman Norman Oklahoma
Lynn Health Science Institute Oklahoma City Oklahoma
Velocity Clinical Research, Medford Medford Oregon
Altoona Center for Clinical Research Duncansville Pennsylvania
Tribe Clinical Research Greenville South Carolina
Coastal Carolina Research Center_North Charleston North Charleston South Carolina
Velocity Clinical Research Dallas Dallas Texas
Valley Institute of Research, Rockwood Medical Clinic Fort Worth Texas
Be Well Clinical Studies - Round Rock Round Rock Texas
Flourish Research, Legacy Oaks Tower San Antonio Texas
Endeavor Clinical Trials San Antonio Texas
Consano Clinical Research, LLC Shavano Park Texas
Charlottesville Medical Research Charlottesville Virginia
Rainier Clinical Research Center Renton Washington

On this site

📄 Praluent (alirocumab) drug profile →

More Regeneron Pharmaceuticals trials in the USA

A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy Active, not recruiting
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma Active, not recruiting
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US Active, not recruiting
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma Active, not recruiting
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment Enrolling by invitation

Other trials for the same condition

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease Starting soon
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension Active, not recruiting
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07477704 on ClinicalTrials.gov ↗ ← All trials in the USA